Does Rallies show Form 4 insider transactions for DMAC?

Yes. Rallies tracks DMAC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is DMAC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DMAC. It does not provide personalized investment advice.

DMAC (DiaMedica Therapeutics Inc. Common Stock) Stock Analysis - Insider Trades

DiaMedica Therapeutics Inc. Common Stock (DMAC) is a publicly traded Healthcare sector company. As of May 20, 2026, DMAC trades at $5.67 with a market cap of $306.06M and a P/E ratio of -8.07. DMAC moved +1.08% today. Year to date, DMAC is -29.76%; over the trailing twelve months it is +30.45%. Its 52-week range spans $3.19 to $10.42. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces DMAC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading DMAC stock inside the company?

Recent DMAC insider activity includes STAHLBERG JAN bought 73.10K, STAHLBERG JAN bought 40.25K, STAHLBERG JAN bought 208.87K, STAHLBERG JAN bought 128.43K, and STAHLBERG JAN bought 240.35K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

DMAC Key Metrics

Key financial metrics for DMAC
Metric	Value
Price	$5.67
Market Cap	$306.06M
P/E Ratio	-8.07
EPS	$-0.70
Dividend Yield	0.00%
52-Week High	$10.42
52-Week Low	$3.19
Volume	80.40K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-32.77M
Gross Margin	0.00%

Recent DMAC Insider Trades

STAHLBERG JAN bought 73.10K (~$626.82K) on Nov 25, 2025.
STAHLBERG JAN bought 40.25K (~$317.72K) on Nov 24, 2025.
STAHLBERG JAN bought 208.87K (~$1.55M) on Nov 21, 2025.
STAHLBERG JAN bought 128.43K (~$951.21K) on Nov 20, 2025.
STAHLBERG JAN bought 240.35K (~$1.73M) on Nov 19, 2025.

Latest DMAC News

DiaMedica Reaches 75% Enrollment and Schedules DSMB Interim Analysis — May 20, 2026
$59.9M Cash Reserves and Positive DM199 Phase 2 Preeclampsia Data — Mar 31, 2026
DiaMedica Secures Health Canada Clearance for Phase 2 Preeclampsia Trial — Mar 5, 2026

DMAC Analyst Consensus

3 analysts cover DMAC: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.

Common questions about DMAC

Who is trading DMAC stock inside the company?: Recent DMAC insider activity includes STAHLBERG JAN bought 73.10K, STAHLBERG JAN bought 40.25K, STAHLBERG JAN bought 208.87K, STAHLBERG JAN bought 128.43K, and STAHLBERG JAN bought 240.35K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for DMAC?: Yes. Rallies tracks DMAC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is DMAC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DMAC. It does not provide personalized investment advice.